Bradley Merrill Thompson, Bonnie I. Scott, and James A. Boiani, attorneys in the Health Care and Life Sciences practice, in the firm’s Washington, DC, office, authored an article in Clinics in Laboratory Medicine Journal titled “Understanding the Food and Drug Administration’s Jurisdiction Over Laboratory-Developed Tests and Divisions Between Food, Drug, and Cosmetic Act-Regulated and Clinical Laboratory Improvement Amendments of 1988-Regulated Activities.” (Read the full version – no subscription required before September 28, 2016.)

Following is an excerpt:

The scope of the Food and Drug Administration’s (FDA’s) jurisdiction over laboratory-developed tests (LDTs), and whether FDA has such jurisdiction at all, has been a heavily debated issue over the past several years. With FDA’s release of draft guidance in October 2014 detailing its proposed framework for regulating many LDTs, the issue has become even more contentious. On a basic level, there are 2 sides to the debate: (1) those who believe FDA’s efforts to expand its authority to regulate LDTs are unlawful and detrimental to the practice of medicine and diagnostic innovation; and (2) those who believe FDA should step in to regulate at least a subset of LDTs due to the potential harm they may cause in the absence of regulation. The former tend to include clinical laboratories and hospitals, whereas the latter tend to include FDA, certain patient groups, and in vitro diagnostics (IVD) manufacturers.

If FDA moves forward with its guidance, or Congress takes action to reform LDT and IVD regulation, a fundamental question that needs to be answered is how to divide activities regulated by the Food, Drug, and Cosmetic Act (FDCA) from those regulated by the Clinical Laboratory Improvement Amendments of 1988 (CLIA). Without a clear framework, any new regulatory system could be a major challenge to navigate, and could lead to duplicative regulation. Unfortunately, in the LDT debate, we rarely get to into these important details because both sides are entrenched in arguing generalities: FDA can do anything it wants or nothing at all with respect to LDTs. Therefore, in this article, we consider FDA’s authority to regulate LDTs and the policy implications of regulation, and discuss an idea for a fact-driven framework to distinguish FDCA and CLIA activities.

Jump to Page

Privacy Preference Center

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer.

Strictly Necessary Cookies

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.